Based on the Sage Therapeutic stock forecast from 15 analysts, the average analyst target price for Sage Therapeutic is USD 13.32 over the next 12 months. Sage Therapeutic’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Sage Therapeutic is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Sage Therapeutic’s stock price was USD 5.61. Sage Therapeutic’s stock price has changed by +4.18% over the past week, +15.67% over the past month and -73.87% over the last year.
No recent analyst target price found for Sage Therapeutic
No recent average analyst rating found for Sage Therapeutic
Company Overview Sage Therapeutic
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Read Less
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteri...Read More
Frequently Asked Questions About Sage Therapeutic (SAGE) Stock
Based on ratings from 15 analysts Sage Therapeutic's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, 2 sell and 19 hold ratings.
Unfortunately we do not have enough data on SAGE's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for SAGE is USD 13.32 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 4.
SAGE stock's Price/Earning ratio is 3.09.
Our analysis grades SAGE stock's Price / Earning ratio at F. This means that SAGE stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SAGE may be fairly valued for its sector
The last closing price of SAGE's stock was USD 5.61.
The most recent market capitalization for SAGE is USD 0.34B.
Based on targets from 15 analysts, the average taret price for SAGE is projected at USD 13.32 over the next 12 months.
This means that SAGE's stock price may go up by +137.41% over the next 12 months.
We can't find any ETFs which contains Sage Therapeutic's stock.
As per our most recent records Sage Therapeutic has 487 Employees.
Sage Therapeutic's registered address is 215 First Street, Cambridge, MA, United States, 02142.
You can get more information about it from Sage Therapeutic's website at https://www.sagerx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Sage Therapeutic (SAGE) Stock
Based on ratings from 15 analysts Sage Therapeutic's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, 2 sell and 19 hold ratings.
Unfortunately we do not have enough data on SAGE's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for SAGE is USD 13.32 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 4.
SAGE stock's Price/Earning ratio is 3.09.
Our analysis grades SAGE stock's Price / Earning ratio at F. This means that SAGE stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SAGE may be fairly valued for its sector
The last closing price of SAGE's stock was USD 5.61.
The most recent market capitalization for SAGE is USD 0.34B.
Based on targets from 15 analysts, the average taret price for SAGE is projected at USD 13.32 over the next 12 months.
This means that SAGE's stock price may go up by +137.41% over the next 12 months.
We can't find any ETFs which contains Sage Therapeutic's stock.
As per our most recent records Sage Therapeutic has 487 Employees.
Sage Therapeutic's registered address is 215 First Street, Cambridge, MA, United States, 02142.
You can get more information about it from Sage Therapeutic's website at https://www.sagerx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SAGE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
